News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Rein Therapeutics announced its financial results for the second quarter ended June 30, 2026, highlighting significant progress in its global Phase 2 RENEW trial for LTI-03 in idiopathic pulmonary fibrosis (IPF), having surpassed 25% enrollment and being on track for interim data in H2 …
Rein Therapeutics Inc. (NASDAQ:RNTX) has received a consensus "Hold" rating from four brokerages, with an average 12-month price target of $6.00. Institutional investors hold a significant 90.89% stake in the company, with several firms recently increasing their positions. The company reported a narrower-than-expected quarterly …
Rein Therapeutics (NASDAQ:RNTX) saw its shares decline by 2.9% on Monday, closing at $0.794. The stock traded below its 50-day and 200-day moving averages and had a market capitalization of $67.92 million. Analyst sentiment is mixed, with a consensus "Hold" rating and an average …
The article provides an earnings forecast for Rein Therapeutics Inc (RNTX), highlighting its current earnings forecast score of 7.33 and an average price target of $8.00 based on 3 analysts. Most analysts recommend a "Buy" rating for RNTX, with a significant upside potential. The …
This article provides an update on Rein Therapeutics Inc (RNTX) stock, noting its current trading price of $0.818, a gain of 3.68%. It indicates that more news regarding earnings, analyst ratings, and key developments will be available soon. The company is in the Biotechnology …
Rein Therapeutics Inc (RNTX) is currently in the "Fair zone" according to its forward P/S ratio of 0.00 compared to its five-year average of -1.69. The article provides various valuation metrics for RNTX, including Price-to-Book (P/B) ratio, Forward Free Cash Flow (FCF) yield, and …
Rein Therapeutics announced the publication of clinical data for its inhaled IPF candidate, LTI-03, in Nature Communications. The study, involving 24 IPF patients, demonstrated that LTI-03 was well-tolerated and significantly reduced multiple biomarkers associated with fibrosis and inflammation in the lungs after just 14 …
Rein Therapeutics Inc (RNTX) has an institutional shareholding score of 3.00, ranking 191 out of 384 in its industry. The institutional shareholding proportion is 16.21%, a decrease of 51.20% quarter-over-quarter. James Simons is the largest institutional shareholder, and other notable shareholders include Voss Capital …
This article presents a financial health analysis of Rein Therapeutics Inc (RNTX) by TradingKey. The company's financial score is 5.52, ranking it low within the Biotechnology & Medical Research industry, indicating weak financial status and low operating efficiency. The analysis highlights that relevant financial …
This article provides a comprehensive stock analysis of Rein Therapeutics Inc (RNTX) by TradingKey, highlighting its weak fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. Despite institutional confidence and a "Buy" rating from multiple analysts with a …
This article provides a detailed cash flow statement for Rein Therapeutics Inc (RNTX), encompassing quarterly and annual data for operating, investing, and financing activities. It presents financial figures such as net income, operating gains/losses, changes in working capital, and different cash flow categories, along …
This article provides a technical analysis of Rein Therapeutics Inc (RNTX), detailing its current price momentum score, support and resistance levels, and various technical indicators. It shows that RNTX has a momentum score of 4.49, is trading between 0.68 and 0.97, and has several …
This article provides historical dividend and stock split information for Rein Therapeutics Inc (RNTX). It indicates that the company has not distributed any dividends over the past five years. The only stock split activity recorded was a 20-to-1 merger on November 10, 2022.
The article provides a financial overview of Rein Therapeutics, Inc. (NASDAQ: RNTX) on TradingView, focusing on its revenue breakdown. It indicates that further details regarding segment and regional performance by source and country are available. The page seems to be a placeholder or incomplete …
This page provides live quotes and charts for Rein Therapeutics Inc. (RNTX), showing its current stock price and a slight daily decrease. It indicates that there are no analyst ratings or earnings information currently available for the company. The page also includes general information …
Rein Therapeutics (RNTX) has released a summary of its proxy filing for the annual meeting scheduled on July 20, 2026. Shareholders as of May 21, 2026, are eligible to vote on key proposals including the election of two Class III directors, an increase in …
This article provides a valuation analysis for Rein Therapeutics Inc (RNTX), noting its current valuation score of 8.49, ranking 127 out of 386 in the Biotechnology & Medical Research industry. It details the company's P/E ratio, which is -0.42, and mentions that P/B and …
Rein Therapeutics (RNTX) reported its Q4 2025 earnings, highlighting a net loss of $49.9 million for the year and a decrease in R&D and G&A expenses. The company paused its LTI-01 and preclinical programs due to capital constraints, focusing resources on its lead candidate, …
Rein Therapeutics announced that its Phase 2 RENEW trial for an undisclosed therapeutic is now enrolling patients across all five participating countries. This marks a significant milestone in the development of the company's treatment.
Rein Therapeutics announced that its Phase 2 RENEW clinical trial for idiopathic pulmonary fibrosis (IPF) has expanded to Germany, bringing the total number of participating countries to five. The trial is evaluating the inhaled therapy LTI-03 in approximately 120 patients and aims to report …
Rein Therapeutics announced that its Phase 2 RENEW trial for inhaled LTI-03 in idiopathic pulmonary fibrosis (IPF) is now enrolling patients across five countries, including the newly added Germany. The trial aims to enroll approximately 120 patients to evaluate LTI-03's efficacy, with initial topline …
Maxim Group has initiated coverage on Rein Therapeutics (RNTX) with a "Buy" rating and a $4.00 price target, signaling a positive outlook for the clinical-stage biopharmaceutical company. Despite a low GF Score™ of 29/100, indicating challenges in profitability, insider purchases totaling $74,413 suggest confidence …
Maxim Group has set a price target of $4.00 per share for Rein Therapeutics, implying a significant upside from its current trading price. The analyst rating suggests a positive outlook for the company's stock performance. This target provides investors with an expectation of potential …
The Rein Therapeutics (RNTX) 2026 Annual General Meeting (AGM) took place virtually, with a quorum of 74.47% shares represented. Key outcomes included the election of two Class III directors, approval to increase authorized shares, appointment of CBIZ as the independent audit firm, and a …
Voss Capital and its affiliated entities, including Voss Value Master Fund and Voss Value-Oriented Special Situations Fund, have filed an amended Schedule 13G/A disclosing a beneficial ownership of approximately 6.6% of Rein Therapeutics (RNTX) common stock. This stake, totaling 5,656,957 shares, includes shares held …
Search by ticker symbol or company name and select a result to open its chart.